MedTrace Logo

Prednisone Treatment for Vestibular Neuronitis

NCT00271791 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2007-11-06

No results posted yet for this study

Summary

The purpose of the study is to investigate the value of steroids in the treatment of vestibular neuronitis. The potential benefits of steroid therapy would be analyzed by the clinical response, self-perceived handicap and laboratory parameters.

Conditions

  • Vestibular Diseases
  • Vestibular Neuronitis

Interventions

DRUG

Prednisone

PO, 1 mg/kg body weight, 5 days Short tapering regimen: daily reductions in the dose, 12 days

DRUG

Prednisone

PO, Placebo, 17 days

Sponsors & Collaborators

  • Clalit Health Services, Haifa and West Galilee

    collaborator OTHER

  • Hillel Yaffe Medical Center

    collaborator OTHER_GOV

  • Rambam Health Care Campus

    collaborator OTHER

  • University Health Network, Toronto

    collaborator OTHER

  • Carmel Medical Center

    lead OTHER

Principal Investigators

  • Avi Shupak, MD · Carmel Medical Center and Clalit Health Services, Haifa and West Galilee

  • Itzhak Braverman, MD · Hillel Yaffe Medical Center

  • Avishai Golz, MD · Rambam Health Care Campus

  • Elhanan Greenberg, ND · Carmel Medical Center

  • Avi Shupak, MD · Carmel Medical Center and Clalit Health Services, Haifa and West Galilee

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2007-05-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00271791 on ClinicalTrials.gov